MedKoo Cat#: 413363 | Name: CS-003 Free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CS-003 Free base is a triple tachykinin receptor antagonist, shows high affinities for human (Neurokinin) NK1, NK2 and NK3 receptors with Ki values of 2.3 nM, 0.54 nM and 0.74 nM, respectively. CS-003 Free base (CS-003) has therapeutic efficacy on respiratory diseases associated with neurokinins.

Chemical Structure

CS-003 Free base
CS-003 Free base
CAS#191672-52-3 (Free Base)

Theoretical Analysis

MedKoo Cat#: 413363

Name: CS-003 Free base

CAS#: 191672-52-3 (Free Base)

Chemical Formula: C34H38Cl2N2O6S

Exact Mass: 672.1828

Molecular Weight: 673.65

Elemental Analysis: C, 60.62; H, 5.69; Cl, 10.52; N, 4.16; O, 14.25; S, 4.76

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
CS-003 Free base; CS003 Free base; CS 003 Free base
IUPAC/Chemical Name
((2R)-2-(3,4-Dichlorophenyl)-2-(2-(2-oxospiro(1H-2-benzothiophene-3,4'-piperidine)-1'-yl)ethyl)morpholin-4-yl)-(3,4,5-trimethoxyphenyl)methanone
InChi Key
RWSBBXFLRGQFQP-KHIDOSKGSA-N
InChi Code
InChI=1S/C34H38Cl2N2O6S/c1-41-29-18-24(19-30(42-2)31(29)43-3)32(39)38-16-17-44-33(22-38,25-8-9-27(35)28(36)20-25)10-13-37-14-11-34(12-15-37)26-7-5-4-6-23(26)21-45(34)40/h4-9,18-20H,10-17,21-22H2,1-3H3/t33-,45?/m0/s1
SMILES Code
O=C(N1C[C@@](CCN2CCC3(CC2)C4=CC=CC=C4CS3=O)(C5=CC=C(Cl)C(Cl)=C5)OCC1)C6=CC(OC)=C(OC)C(OC)=C6
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
Soluble in DMSO 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 673.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tsuchida H, Takahashi S, Nosaka E, Mukaiyama O, Yamashita M, Morimoto K. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses. Eur J Pharmacol. 2008 May 31;586(1-3):306-12. doi: 10.1016/j.ejphar.2008.02.056. Epub 2008 Mar 4. PMID: 18353309. 2: Tsuchida H, Takahashi S, Nosaka E, Kuraya T, Yamashita M, Morimoto K. Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs. Eur J Pharmacol. 2008 Oct 31;596(1-3):153-9. doi: 10.1016/j.ejphar.2008.07.046. Epub 2008 Jul 31. PMID: 18706408. 3: Schelfhout V, Louis R, Lenz W, Heyrman R, Pauwels R, Joos G. The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthma. Pulm Pharmacol Ther. 2006;19(6):413-8. doi: 10.1016/j.pupt.2005.10.007. Epub 2005 Dec 20. PMID: 16364669. 4: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Nov;25(9):747-71. PMID: 14685303. 5: Noritake K, Suzuki J, Matsuoka T, Makino T, Ohnishi H, Shimomura K, Uenoyama Y, Tsukamura H, Maeda K, Sanbuissho A. Testicular toxicity induced by a triple neurokinin receptor antagonist in male dogs. Reprod Toxicol. 2011 May;31(4):440-6. doi: 10.1016/j.reprotox.2010.12.007. Epub 2010 Dec 23. PMID: 21185367. 6: Noritake K, Matsuoka T, Ohsawa T, Shimomura K, Sanbuissho A, Uenoyama Y, Maeda K, Tsukamura H. Involvement of neurokinin receptors in the control of pulsatile luteinizing hormone secretion in rats. J Reprod Dev. 2011 Jun;57(3):409-15. doi: 10.1262/jrd.11-002s. Epub 2011 Feb 25. PMID: 21358144. 7: Kumon M, Yabe Y, Kasuya Y, Suzuki M, Kusai A, Yonemochi E, Terada K. Applicability of DPI formulations for novel neurokinin receptor antagonist. Int J Pharm. 2008 May 22;356(1-2):102-9. doi: 10.1016/j.ijpharm.2007.12.044. Epub 2008 Jan 9. PMID: 18294787.